Table 1. Biological Responses Mediated by Adrenergic Receptors in the Human Heart Biological ResponseAdrenergic Receptor Mediation Cardiac myocyte growthß.

Slides:



Advertisements
Similar presentations
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 19 Adrenergic-Blocking Drugs.
Advertisements

Jara – Medrano (“Jarano”). * Indications: acute bronchospasm, severe bronchospasm, acute severe asthma * Pharmacokinetics: * Route: Inhaled, oral * Absorption:
Adrenoceptor antagonist drugs Department of pharmacology Zhu ling ( 朱玲 )
Adrenergic-Blocking Drugs
B) Drug Therapy (Antihypertensives) ACEi B.B CCB D iuretics. Centrally acting agents: alphametyldopa, HTN + pregnancy.
Pharmacology II The Autonomic Nervous System Adrenergic antagonists
Beta-Adrenergic Blockers  Types of adrenoceptors Alpha-1  Vasoconstriction  Increased peripheral resistance  Increased blood pressure Alpha-2  Inhibition.
Alpha-Adrenergic Blockers
ALPHA BLOCKERS Alpha receptors have been further subdivided into alpha1 and alpha2 receptors. Alpha -1 receptors – Upon stimulation, leads to increased.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 18 Adrenergic Antagonists.
Drugs for Hypertension
Heart Failure. How do  -blockers work? Mechanism for How It Works ・ Beta-blockers "block" the effects of adrenaline on your body's beta-receptors. This.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 18 Adrenergic-Blocking Drugs.
Chapter 18 Agents that Dilate Blood Vessels. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Coronary.
Adrenoceptor Blockers
ADRENERGIC ANTAGONITS
Head Lines Etiology Risk factors Mechanism Complications Treatment.
Adrenergic antagonist sympatholytic
Adrenergic Antagonist (Sympatholytics)
Adrenergic Blocking Drugs
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 19 Indirect-Acting Antiadrenergic Agents.
Beta Blockers.
ANTI-ADRENERGIC DRUGS
HuBio 543 September 27, 2007 Neil M. Nathanson K-536A, HSB
Adrenolytics. Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics Alpha & beta- adrenergic receptor blockers.
Adrenergic preparations
Drugs Affecting Blood Pressure Brenda B. Rowe. Vasopressors Treat shock Treat shock Dopamine (Intropin) – stimulates alpha-1 & beta-1 Dopamine (Intropin)
Bipyridines :(Amrinone,Milrinone ) only available in parenteral form. Half-life 3-6hrs. Excreted in urine.
6/3/ CARDIOVASCULAR MEDICATIONS. FIRST DO NO HARM 6/3/ There are 5 rights to patient medication administration: 1. Right patient 2. Right.
Adrenergic Receptor Antagonists Excessive sympathetic activity is characteristic of a number of pathological states including: Hypertension Angina pectoris.
 Cardiovascular Effects  α -receptor antagonist drugs lower peripheral vascular resistance and blood pressure.  These drugs can prevent the pressor.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 46 Vasodilators.
Alpha & beta- adrenergic receptor blockers Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics  Form False Transmitters  Deplete.
BETA ADRENOCEPTOR BLOCKERS. OCH 2 CH CH 2 NHCH CH 3 OH CH 2 CH CH 2 NHCH OH CH 3 CH 3 OCHCH 2 PROPRANOLOL METOPROLOL.
Adrenergic Antagonists (Sympatholytics)
بسم الله الرحمن الرحيم.
PHARMACOLOGY OF ANS part 3 General Pharmacology M212
Sympathetic Nervous System.
Adrenergic Antagonists
 - Adrenoceptors blockers Prof. Hanan Hagar Pharmacology Unit College of Medicine.
SYMPATHOLYTIC AGENTS Beta Receptor Blockers. BETA-ADRENERGIC RECEPTOR BLOCKERS  Widely used clinically for a variety of conditions ; mainly CVS  Dichloro-isoproterenol.
PHARMACOLOGY OFADRENERGICS
 Prazosin, doxazosin, and terazosin  They causing relaxation of both arterial and venous smooth muscle. Postural hypotension may occur in some individuals.
-ADRENOCEPTOR ANTAGONISTS
Adrenergic Antagonists (Sympatholytics). Basic stages in synaptic transmission.
1 ADRENERGIC ANTAGONITS. 2 ADRENERGIC BLOCKERS ALPHA BLOCKERS Alpha 1 Blockers Nonselective Alpha Blockers Doxazosin Phenoxybenzamine Prazosin Phentolamine.
Sympatholytic & adrenergic blockers -receptor Antagonists
Adrenergic Antagonists
Alpha & beta- adrenergic receptor blockers Adrenoceptor Blockers Adrenolytics Adrenergic Neuron Blockers Sympatholytics  Form False Transmitters  Deplete.
Investigation of the effects of ß-blockers on CVS
PHARMACOLOGY OFADRENERGICS
Sympatholytic & adrenergic blockers -receptor Antagonists
β-adrenergic antagonists
Drugs for Hypertension
- Adrenoceptors blockers
Drugs Affecting the Cardiovascular System
Sympatholytic & adrenergic blockers -receptor Antagonists
β – ADRENERGIC BLOCKERS
ANTI HYPERTENSIVE DRUGS
ANTI HYPERTENSIVE DRUGS
Beta-adrenergic blocking agents
Effect of β-adrenergic Blockers on the Arterial Blood Pressure
Anti hypertensive Drugs
Beta blockers and anesthesia
CHAPTER 18 Adrenergic-Blocking Drugs
- Adrenoceptors blockers
Sympatholytic & adrenergic blockers -receptor Antagonists
Adrenergic Antagonists
Chaper 20 Adrenoceptor Antagonists
Presentation transcript:

Table 1. Biological Responses Mediated by Adrenergic Receptors in the Human Heart Biological ResponseAdrenergic Receptor Mediation Cardiac myocyte growthß 1, ß 2, 1 Positive inotropic responseß 1, ß 2, 1 (minimal) Positive chronotropic responseß 1, ß 2 Myocyte toxicityß 1, ß 2 (?<ß 1 ) Myocyte apoptosisß1ß1

Properties of Beta-blockers Potency Membrane stabilizing activity (quinidine-like) Structure-activity relationships: L-isomer has the Beta-blocking action. Cardioselectivity (Beta-1 selectivity) Intrinsic sympathomimetic activity (partial agonist activity) Lipid solubility – relation to pharmacokinetics

Pharmacologic Differences between  -Blockers Selective vs nonselective Alpha-adrenergic blocking properties Additional properties (e.g., antioxidant) Intrinsic sympathomimetic activity (ISA) Inverse agonism Receptor upregulation Effects on catecholamine levels

Beta-Blockers Pharmacokinetics Lipid soluble agents (vs. water soluble) tend to: – Be better absorbed – Have more variable bioavailability – Be metabolized in liver – Enter the CNS – Be more widely distributed – Have shorter elimination half-lives

Beta-Blockers - Adverse Effects Cardiac (mechanical; electrical) Vascular (decreased perfusion) Pulmonary (bronchocostriction) Metabolic (diabetes mellitus) Central Nervous System (depression, nightmares, etc.) Withdrawal Syndrome

Cardioselective Blockers - advantages In asthma In diabetes mellitus In peripheral vascular disease In hypertension (?)

NamePot.Beta -1 ISAMSAt1/2 (h) Lipid Sol. 1 st Pass % Abs. % Bioav. Elim Propranolol (Inderal) HighYes>9030Hep; AM Nadolol (Blocadren) Weak30 Ren Timolol (Blocadren) 64-5ModLittle>9075Ren Metoprolol (Lopressor) ModYes>9050Hep Atenolol (Tenormin) Weak5040Ren Esmolol (Brevibloc) minWeakNA Blood esterases Pindolol (Visken) High>9090Ren/Hep Acebutalol (Sectral) ModLittle7040Ren/Hep ;AM Sotalol * (Sotapor) Weak7060Ren Labetalol # (Normodyne) ModYes>9033Hep *: Class III antiarrhythmic; #: an alpha-1 blocker also. ISA: intrinsic sympathomimetic activity; MSA: membrane stabilizing activity. AM: active metabolite. Many other Beta blockers available.

Beta-Blockers Therapeutic Uses Coronary artery disease Hypertension Arrhythmias Congestive heart failure Hypertrophic obstructive cardiomyopathy Dissecting aortic aneurysm Pheochromocytoma Hyperthyroidism Migraine -prophylaxis Essential tremor Anxiety – stage fright Glaucoma (topical)

Antihypertensive Effect of Beta- Blockers Mechanisms 1. Decreased cardiac output 2. Inhibition of renin-angiotensin system 3. Decreased central sympathetic outflow 4. Resetting of baroreceptor 5. Others: prejunctional receptors, prostaglandins, etc.

Stable Angina Current Pharmacotherapy Beta-blockers Calcium channel blockers Nitrates Aspirin Statins ? ACE inhibitors

Beta-Blockers Decrease myocardial oxygen consumption Blunt exercise response Beta-one drugs have theoretical advantage Try to avoid drugs with intrinsic sympathomimetic activity First line therapy in all patients with angina if possible

Beta-Blockers

Effects of Sympathetic Activation in Heart Failure  1 - receptors  Cardiac sympathetic activity  Sympathetic activity to kidneys + blood vessels  2 - receptors  1 - receptors Activation of RAS Vasoconstriction Sodium retention Myocyte death Increased arrhythmias Disease progression 1-1- 1-1-  CNS sympathetic outflow

Adapted from Bristow MR. J Am Coll Cardiol. 1993;22(4 Suppl A):61A–71A. In the damaged heart, the ratio of receptors shifts, increasing the relative proportion of  2 - and  1 -receptors The Ratio of  2 - and  1 -Adrenergic Receptors in the Damaged Heart

C3= legame per zuccheri pentosi, esosi; C17= anello lattonico insaturo; C14= ossidrile

Inotropo positivi non digitalici Dopamina Dobutamina Ibopamina Amrinone Milrinone Levosimendan

Blood Pressure Regulation Sympathetic nervous control

Centrally Acting Drugs  Antihypertensive effect results from action in the CNS causing a reduced sympathetic nerve firing rate.  Prototype: clonidine

Centrally Acting Drugs  Clonidine activates alpha 2 and imidazoline receptors in the vasomotor center of the medulla which inhibits the sympathetic nervous system.  Considered a second-line drug or for special cases (ie methyldopa in pregnant hypertensive patients).  A reduced heart rate and cardiac output account for reduction in blood pressure.

Centrally Acting Drugs  An advantage of these drugs is that they do not cause postural hypotension  Side effects - hypertensive rebound if there is an abrupt withdrawal -dry mouth, sedation